Atopic DermatitisNCT07323394
Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
An observational study of Atopic Dermatitis and Eczema Atopic Dermatitis, run by PeriPharm.
Trial summary
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Atopic Dermatitis, Eczema Atopic Dermatitis, Eczema
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Jan 2026to Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis
Who may be able to join
- Aged ≥18 years;
- Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;
- Able to read and understand French or English;
- Willing and able to provide written informed consent.
Who cannot join
- Caregivers whose child has been diagnosed with severe atopic dermatitis ;
- Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);
- Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;
- Other parent or caregiver within the household of the child with atopic dermatitis.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.
- Conditions
- Atopic Dermatitis, Eczema Atopic Dermatitis, Eczema, Caregiver, Burden
- Being tested
- No Intervention: Observational Cohort
- Keywords
- atopic dermatitis, quality of life, real-world
- Medical subject headings
- Dermatitis, Atopic, Eczema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
No specific intervention is assess in this study. Observational cohort.
| Study group | Role | What they receive |
|---|---|---|
| Caregiver of child with atopic dermatitis | Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
To estimate work productivity loss in caregivers of children with mild or moderate atopic dermatitis.
Using the Work Productivity and Activity Impairment questionnaire. This questionnaire provides a quantitative measure of impairment over the last 7 days and includes four metrics: absenteeism (work time missed because of health issues during the past 7 days), presenteeism (impairment while working due to health issues during the past 7 days), overall work productivity loss (combination of absenteeism and presenteeism), and activity impairment.
Measured: At recruitment
Secondary outcomes (1)
To estimate family burden of mild to moderate atopic dermatitis in children, as reported by caregivers
The Dermatitis Family Impact (DFI) questionnaire will be administered to caregivers to evaluate the family burden of pediatric atopic dermatitis. The DFI is a validated, 10-item instrument specifically developed for atopic dermatitis, covering domains such as housework, feeding, sleep, leisure activities, time spent shopping, expenditure, physical fatigue, emotional distress, relationships, helping with treatment, with a 7-day recall period. Each item is scored on a 4-point Likert scale ("Not at all = 0" to "Very much = 3"), with higher total scores indicating greater impact
Measured: At recruitment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionJun 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- PeriPharm
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07323394
- Sponsor's protocol ID
- PROxy96AD
- Status last verified
- Jan 2026
- First submitted
- 22 Dec 2025
- Last updated
- 23 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
- ClinicalTrials.gov ID
- NCT07323394
- Acronym / sponsor ID
- PROxy96AD
- Conditions
- Atopic Dermatitis, Eczema Atopic Dermatitis, Eczema, Caregiver, Burden
- Keywords
- atopic dermatitis, quality of life, real-world
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- PeriPharmUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Caregiver of child with atopic dermatitis | – | Other: No Intervention: Observational CohortCaregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis
Key inclusion criteria (4 listed)
- Aged ≥18 years;
- Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;
- Able to read and understand French or English;
- Willing and able to provide written informed consent.
Key exclusion criteria (4 listed)
- Caregivers whose child has been diagnosed with severe atopic dermatitis ;
- Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);
- Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;
- Other parent or caregiver within the household of the child with atopic dermatitis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortNo specific intervention is assess in this study. Observational cohort. | Other | Caregiver of child with atopic dermatitis |
Primary outcome
To estimate work productivity loss in caregivers of children with mild or moderate atopic dermatitis.
Time frame: At recruitment
Using the Work Productivity and Activity Impairment questionnaire. This questionnaire provides a quantitative measure of impairment over the last 7 days and includes four metrics: absenteeism (work time missed because of health issues during the past 7 days), presenteeism (impairment while working due to health issues during the past 7 days), overall work productivity loss (combination of absenteeism and presenteeism), and activity impairment.
1 secondary outcome
To estimate family burden of mild to moderate atopic dermatitis in children, as reported by caregivers
Time frame: At recruitment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Atopic Dermatitis and Eczema Atopic Dermatitis, run by PeriPharm.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jean Lachaine, Ph. D. (514-731-8207, jean.lachaine@peripharm.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To estimate work productivity loss in caregivers of children with mild or moderate atopic dermatitis. (time frame: At recruitment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.